AbClon Inc.
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
174900 | KO
Overview
Corporate Details
- ISIN(s):
- KR7174900001
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 구로구 디지털로 285 에이스트윈타워 1차 1401호, 구로구
- Website:
- https://www.abclon.com/en/
- Sector:
- Manufacturing
Description
AbClon Inc. is a clinical-stage company focused on the research and development of antibody-based therapeutics. The company leverages three core proprietary platforms. The CAR-T platform develops personalized cell therapies for cancer patients by engineering a patient's own immune cells to target and destroy cancer cells, with a focus on blood cancers. The NEST (Novel Epitope Screening Technology) platform is designed to discover antibodies that target unique, previously unaddressed sites on disease proteins, enabling novel therapeutic effects. The AffiMab platform facilitates the development of bispecific antibodies that can simultaneously engage two different disease targets, aiming to maximize therapeutic efficacy in refractory diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-03-23 00:00 |
[기재정정]주주총회소집공고
|
Korean | 109.6 KB | ||
| 2022-03-21 00:00 |
사업보고서 (2021.12)
|
Korean | 1.1 MB | ||
| 2022-03-18 00:00 |
감사보고서제출
|
Korean | 20.4 KB | ||
| 2022-03-04 00:00 |
주주총회소집공고
|
Korean | 100.9 KB | ||
| 2022-03-04 00:00 |
의결권대리행사권유참고서류
|
Korean | 104.4 KB | ||
| 2022-02-22 00:00 |
주주총회소집결의
|
Korean | 10.5 KB | ||
| 2022-02-04 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | 11.1 KB | ||
| 2022-02-04 00:00 |
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | 15.6 KB | ||
| 2021-12-28 00:00 |
투자판단관련주요경영사항(재발성 또는 불응성 B세포 비호지킨 림프종 환자에서 AT101 (항-CD19 키메릭항원수용체 T세포)의 안전성, 내약성…
|
Korean | 11.8 KB | ||
| 2021-12-14 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2021-11-11 00:00 |
분기보고서 (2021.09)
|
Korean | 994.1 KB | ||
| 2021-10-29 00:00 |
기타경영사항(특허권취득)(자율공시)(안정성이 개선된 HER2에 특이적으로 결합하는 항체)
|
Korean | 6.5 KB | ||
| 2021-08-13 00:00 |
반기보고서 (2021.06)
|
Korean | 962.9 KB | ||
| 2021-06-24 00:00 |
투자판단관련주요경영사항(재발성 또는 불응성 B세포 비호지킨 림프종 환자에서 AT101 (항-CD19 키메릭항원수용체 T세포)의 안전성, 내약성…
|
Korean | 11.0 KB | ||
| 2021-06-03 00:00 |
[기재정정]사업보고서 (2020.12)
|
Korean | 1.1 MB |
Automate Your Workflow. Get a real-time feed of all AbClon Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for AbClon Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for AbClon Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
